Skip to main content

Table 1 Patients’ background before administration of recombinant thrombomodulin

From: Administration of recombinant thrombomodulin before progression of disease causing disseminated intravascular coagulation might be better compared with administration after progression of disease

 

Group S (n = 57)

Group NS (n = 44)

pvalue

Age, years, mean ± SD

68 ± 17

75 ± 11

0.036

Height, cm, mean ± SD

157 ± 8

157 ± 8

0.71

Weight, kg, mean ± SD

49 ± 10

58 ± 12

<0.001

BMI, kg/m2, mean ± SD

20 ± 4

23 ± 4

<0.001

Gender, female, n

27

10

0.011

Infection-induced DIC, n

48

38

0.76

Intra-abdominal, n

29

24

 

Lung, n

9

10

 

Urinary, n

3

0

 

Others, n

7

4

 

Non-infection-induced DIC, n

9

6

0.34

Obstetric, n

2

0

 

Intestinal ischemia, n

2

3

 

Others, n

5

3

 

Heart disease, n

12

15

0.14

Diabetes mellitus, n

15

16

0.27

Hypertension, n

30

22

0.79

Smoking, n

19

22

0.091

  1. BMI body mass index, DIC disseminated intravascular coagulation.